Human CD4, His Tag (LE3-H5228) is expressed from human 293 cells (HEK293). It contains AA Lys 26 - Trp 390 (Accession # AAH25782).
Predicted N-terminus: Lys 26
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 41.5 kDa. The protein migrates as 47-54 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Human CD4, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Ibalizumab at 1 μg/mL (100 μL/well) can bind Human CD4, His Tag (Cat. No. LE3-H5228) with a linear range of 0.8-6 ng/mL (QC tested).
Immobilized Human CD4, His Tag (Cat. No. LE3-H5228) at 1 μg/mL (100 μL/well) can bind Ibalizumab with a linear range of 0.2-13 ng/mL (Routinely tested).
Immobilized Human CD4, His Tag (Cat. No. LE3-H5228) at 2 μg/mL (100 μL/well) can bind Anti-CD4 with a linear range of 0.4-7 ng/mL (Routinely tested).
T-cell surface glycoprotein CD4 is also known as T-cell surface antigen T4/Leu-3. CD4 contains three Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. CD4 is accessory protein for MHC class-II antigen/T-cell receptor interaction. CD4 induces the aggregation of lipid rafts. CD4 is a primary receptor used by HIV-1 to gain entry into host T cells. HIV infection leads to a progressive reduction of the number of T cells possessing CD4 receptors. Therefore, medical professionals refer to the CD4 count to decide when to begin treatment for HIV-infected patients.